Innoviva (INVA) Cost of Revenue (2011 - 2026)

Innoviva's Cost of Revenue history runs 7 years deep, the most recent figure standing at $15.6 million for Q1 2026.

• Quarterly Cost of Revenue rose 76.51% year-over-year to $15.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $80.1 million (up 38.8% YoY) and the FY2025 annual result came in at $77.4 million, changed N/A from the prior year.
• Cost of Revenue was $15.6 million for Q1 2026 at Innoviva, down from $45.1 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $45.1 million in Q3 2025 and bottomed at $1.6 million in Q1 2023.
• A 5-year average of $13.2 million and a median of $9.0 million in 2023 frame the typical range for Cost of Revenue.
• Annual changes were most pronounced in 2023 — Cost of Revenue plunged 56.52% — and 2024, when it jumped 1739.56%.
• Innoviva's Cost of Revenue stood at $3.7 million in 2022, then slumped by 56.52% to $1.6 million in 2023, then soared by 1739.56% to $29.4 million in 2024, then surged by 53.14% to $45.1 million in 2025, then sank by 65.38% to $15.6 million in 2026.
• Business Quant data shows INVA's Cost of Revenue at $15.6 million in Q1 2026, $45.1 million in Q3 2025, and $10.6 million in Q2 2025.